Trissel Lawrence A, Xu Quanyun A, Pham Lien
Clinical Pharmaceutics Research, Division of Pharmacy, The University of Texas, M.D. Anderson Cancer Center, Houston, TX.
Int J Pharm Compd. 2002 Jan-Feb;6(1):74-6.
The objective of this study was to evaluate the physical and chemical stability of hydromorphone hydrochloride in concentrations of 1.5 and 80 mg/mL in 0.9% sodium chloride injection packaged in plastic syringes. Test samples of hydromorphone hydrochloride 1.5- and 80-mg/mL solutions were packaged as 20 mL of drug solution in 30-mL plastic syringes, sealed with plastic tip caps, and stored at 4 deg C and 23 deg C for 60 days and at -20 deg C and 37 deg C (temperature extremes that might be encounterd during shipping) for 2 days. Evaluations for physical and chemical stability were performed initially and throughout the storage periods. Physical stability was assessed by means of visual observation in normal room light with a high-intensity monodirectional light beam. In addition, turbidity and particle content were measured electronically. The chemical stability of the drug was evaluated by means of a stability-indicating high-performance liquid chromatographic (HPLC) analytical technique. All samples of hydromorphone hydrochloride remained free of visible precipitation throughout the study. Those solutions stored at 4 deg C, 23 deg C, or 37 deg C exhibited little or no change in measured particulate burden and haze level. Freezing the solution resulted in an increase in microparticulate content that did not redissolve when the solution was warmed at room temperature. Little or no loss of hydromorphone hydrochloride occurred in any of the samples at any storage temperature throughout the study. Hydromorphone hydrochloride concentrations were found to be 95% or greater over 60 days at both 4 deg C and 23 deg C; concentrations were greater than 97% at both -20 deg C and 37 deg C after 2 days. Hydromorphone hydrochloride solutions at concentrations ranging from 1.5 to 80 mg/mL in 0.9% sodium chloride injection can be packaged in plastic syringes, stored, and shipped with little or no loss of drug. Freezing should be avoided.
本研究的目的是评估盐酸氢吗啡酮在塑料注射器包装的0.9%氯化钠注射液中浓度为1.5和80mg/mL时的物理和化学稳定性。将1.5mg/mL和80mg/mL的盐酸氢吗啡酮测试样品以20mL药物溶液的形式包装在30mL塑料注射器中,用塑料帽密封,并在4℃和23℃下储存60天,在-20℃和37℃(运输过程中可能遇到的极端温度)下储存2天。在储存期开始时及整个储存期间对物理和化学稳定性进行评估。通过在正常室内光线下用高强度单向光束进行目视观察来评估物理稳定性。此外,用电学方法测量浊度和颗粒含量。通过稳定性指示高效液相色谱(HPLC)分析技术评估药物的化学稳定性。在整个研究过程中,所有盐酸氢吗啡酮样品均未出现可见沉淀。那些在4℃、23℃或37℃下储存的溶液在测量的颗粒负荷和雾度水平上几乎没有变化。溶液冷冻导致微粒含量增加,当溶液在室温下升温时,微粒不会重新溶解。在整个研究过程中,任何储存温度下的任何样品中盐酸氢吗啡酮的损失都很少或没有损失。发现在4℃和23℃下60天内盐酸氢吗啡酮浓度为95%或更高;在-20℃和37℃下2天后浓度均大于97%。浓度范围为1.5至80mg/mL的盐酸氢吗啡酮在0.9%氯化钠注射液中可以包装在塑料注射器中储存和运输,药物损失很少或没有损失。应避免冷冻。